טוען...
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
Cancers of nearly all lineages harbor alterations that deregulate mitogen-activated protein kinase signaling, a crucial signaling pathway for tumor formation and maintenance. Of these, KRAS mutations are the most frequent gain-of-function alterations found in patients with cancer. In particular they...
שמור ב:
| הוצא לאור ב: | Cancer Treat Rev |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7448574/ https://ncbi.nlm.nih.gov/pubmed/32062493 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ctrv.2020.101978 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|